Aquestive Therapeutics, Inc. (AQST) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development Transcript

Group 1 - The presentation is led by David Amsellem from Piper Sandler's Biopharma research team, focusing on the third quarter earnings cycle for Aquestive Therapeutics [1] - The senior leadership team of Aquestive Therapeutics is present, including the President and CEO, CFO, Chief Medical Officer, and other key executives [2] - The ACAAI meeting in Florida is highlighted as an important event where data related to Anaphylm will be presented in the coming days [2]